ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Comorbidity"

  • Abstract Number: 2024 • ACR Convergence 2024

    Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis

    Chio Yokose1, saiajay chigurupati2, Bohang Jiang2, Kiara Tan2, Natalie McCormick2 and Hyon K. Choi3, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
  • Abstract Number: 1116 • ACR Convergence 2024

    Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry

    Shivang Chaudhary1, Kaushik Gokul1, Kishan Patel2, Simran Bhimani3, Yash Deshpande3, Adam Kilian1, Ravi Nayak1, Deana Mikhalkova1 and Chaitanya Rojulpote1, 1Saint Louis University, St. Louis, MO, 2Riverside Community Hospital, Riverside, CA, 3The Wright Center for graduate medical education, Scranton, PA

    Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
  • Abstract Number: 2110 • ACR Convergence 2024

    Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes

    Lauren King1, Alanna Weisman1, Baiju Shah1, Robert Goldberg1, Amish Parikh2, Ian Stanaitis3, Rosane Nisenbaum4, Esther Waugh1, Lorraine Lipscombe1 and Gillian Hawker1, 1University of Toronto, Toronto, ON, Canada, 2Trillium Health Partners, Toronto, ON, Canada, 3Women's College Hospital, Toronto, ON, Canada, 4Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada

    Background/Purpose: There is a high prevalence of knee osteoarthritis (OA) in people with type 2 diabetes (T2D), and knee OA increases risk for diabetes complications…
  • Abstract Number: 1216 • ACR Convergence 2024

    Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions

    Larry Moreland1, Rowe Brookfield2 and Adam Laitman2, 1University of Colorado, Denver, CO, 2Salix Pharmaceuticals, Bridgewater, NJ

    Background/Purpose: In patients taking opioid analgesics, opioid-induced constipation (OIC) is estimated to affect between 41% to 80% of patients and is caused by peripheral mu-opioid…
  • Abstract Number: 2171 • ACR Convergence 2024

    A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers

    Chrysi Stavropoulou1, Corrie Billedeau2, Jennifer Protudjer1 and Carol Hitchon1, 1University of Manitoba, Winnipeg, MB, Canada, 2NA, Winnipeg, MB, Canada

    Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…
  • Abstract Number: 1239 • ACR Convergence 2024

    Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients

    Vanessa Bartsch1, Basel Habboub2, Kathrin Standfest1, Johannes Knitza3, Georg Schett4 and Axel Hueber2, 1Division Rheumatology, Klinikum Nuernberg, Nuernberg, Germany, 2Klinikum Nuernberg, Nuernberg, Germany, 3Institute for Digital Medicine, Philipps-University Marburg and University Hospital of Giessen and Marburg, Marburg, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at higher risk for malignancies and infections. Effective management strategies for these comorbidities are urgently needed. We…
  • Abstract Number: 2230 • ACR Convergence 2024

    Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

    Maria Garcia-Gonzalez1, Fuensanta Gomez-Bernal2, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
  • Abstract Number: 0559 • ACR Convergence 2023

    Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus

    Renata Baronaite Hansen, Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Comorbidity risk is remarkably increased in patients with Systemic Lupus Erythematosus (SLE) compared with the general population. A better understanding of comorbidity development in…
  • Abstract Number: 1542 • ACR Convergence 2023

    The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

    Zachary Wallace1, Xiaoqing Fu2, Shruthi Srivatsan2, Zachary Williams2, Claire Cook2, Jennifer Hanberg2, John Stone3, Hyon K. Choi4 and Yuqing Zhang5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
  • Abstract Number: 0723 • ACR Convergence 2023

    Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

    Xiaoyue Deng1, Junyan Qian1, Ranran Wang2, JIULIANG ZHAO3, Qian Wang4, Tianyi Yuan2, MENGTAO LI1 and Xiaofeng Zeng5, 1Peking Union Medical College Hospital, Beijing, China, 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Beijing Union Medical College Hospital, Beijing, China, 4Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious complication in SLE patients, with rapid progression and poor prognosis. In China, approximately 3% of the over…
  • Abstract Number: 1631 • ACR Convergence 2023

    Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

    Chloe Peyton1, Tate Johnson1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Jill Poole1, Geoffrey Thiele1, Ted R Mikuls3 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
  • Abstract Number: 0739 • ACR Convergence 2023

    Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

    Sali Merjanah1, Devin Driscoll2, Christine Peloquin3, Jean liew3 and Maureen Dubreuil4, 1Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2Boston University/Boston Medical Center, Boston, MA, 3Boston University, Boston, MA, 4Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
  • Abstract Number: 1632 • ACR Convergence 2023

    Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care

    Martin Schaefer1, Yvette Meissner1, Bernhard Manger2, Sylvia Berger3, Karin Rockwitz4, Anne Regierer5 and Anja Strangfeld1, 1German Rheumatism Research Center, Berlin, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Rheumatologist, Naunhof, Germany, 4Rheumatologist, Goslar, Germany, 5Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
  • Abstract Number: 0869 • ACR Convergence 2023

    Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis

    Irene Lorenzo Gomez1, Uxía nogueira Recalde2, Christian García Domínguez1, Natividad Oreiro Villar3, Jose Antonio Pinto Tasende3, Mohit Kapoor4, Francisco J. Blanco3 and Beatriz Carames1, 1Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (iNIBIC), A Coruña, Spain, 2Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 4Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Defects in homeostatic mechanisms, such as autophagy, contribute to joint aging and Osteoarthritis (OA) and precede joint damage (1). OA is a complex and…
  • Abstract Number: 1855 • ACR Convergence 2023

    Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

    Gary Macfarlane1, Roxanne Cooksey2, Ernest Choy3 and Rosemary Hollick4, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Cardiff University, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 4University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology